Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors

Lung Cancer

Volumn 79, Issue 3, 2013, Pages 283-288

  Nishino, Mizuki ^a,b   Cardarella, Stephanie ^b   Dahlberg, Suzanne E ^a   Jackman, David M ^b   Ramaiya, Nikhil H ^a,b   Hatabu, Hiroto ^b   Rabin, Michael S ^b   Jänne, Pasi A ^b   Johnson, Bruce E ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Computed tomography; Drug resistance; EGFR tyrosine kinase inhibitors; Epidermal growth factor receptor mutations; Lung cancer; RECIST

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PACLITAXEL; PEMETREXED;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; DRUG WITHDRAWAL; EXON; FEMALE; FOLLOW UP; GENE DELETION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84873166606     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.11.007     Document Type: Article

References (41)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. American Cancer Society: Cancer facts and figures, 2012. http://www.cancer.org/Research/CancerFactsFigures/ACSPC-031941.
3. van Zandwijk N., Mathy A., Boerrigter L., et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol 2007, 18:99-103.
4. Sequist L.V., Martins R.G., Spigel D., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26:2442-2449.
5. Jackman D.M., Yeap B.Y., Sequist L.V., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:3908-3914.
6. Mok T.S., Wu Y.L., Thongprasert S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
7. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
8. Zhou C., Wu Y.L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
9. Rosell R., Carcereny E., Gervais R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
10. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
11. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
12. Kobayashi S., Boggon T.J., Dayaram T., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
13. Sequist L.V., Waltman B.A., Dias-Santagata D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 23(3). 75ra26.
14. Arcila M.E., Oxnard G.R., Nafa K., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011, 17:1169-1180.
15. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
16. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
17. Wolchok J.D., Hoos A., ODay S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420.
18. Krajewski K.M., Guo M., Van den Abbeele A.D., et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 2011, 59:856-862.
19. Nishino M., Jagannathan J.P., Krajewski K.M., et al. Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-specific and Therapy-specific Response Criteria to Complement Pitfalls of RECIST. AJR Am J Roentgenol 2012, 198:737-745.
20. Riely G.J., Kris M.G., Zhao B., et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007, 13:5150-5155.
21. Jackman D., Pao W., Riely G.J., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28:357-360.
22. Mok T.S. Living with imperfection. J Clin Oncol 2010, 28:191-192.
23. Chaft J.E., Oxnard G.R., Sima C.S., et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011, 17:6298-6303.
24. Camidge D.R. Progression-free survival (PFS) from a phase I study of crizotinib(PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29:165s.
25. Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.
26. Stern H.M. Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med 2012, 4. 127rv2.
27. Heon S., Yeap B.Y., Britt G.J., et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 2010, 16:5873-5882.
28. Jackman D.M., Cioffredi L.A., Lindeman N., et al. Phase II trial of erlotinib in chemotherapy-nave women with advanced pulmonary adenocarcinoma. J Clin Oncol 2009, 27:15s. (suppl; abstr 8065).
29. Jackman D.M., Yeap B.Y., Lindeman N.I., et al. Phase II clinical trial of chemotherapy-naive patients>or 1/4 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007, 25:760-766.
30. Janne P.A., Gurubhagavatula S., Yeap B.Y., et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, " Iressa" ) on an expanded access study. Lung Cancer 2004, 44:221-230.
31. Janne P.A., Wang X.F., Socinski M.A., et al. Randomized phase III trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. J Clin Oncol 2010, 28. (suppl; abstr 7503).
32. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
33. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
34. Nishino M., Jagannathan J.P., Ramaiya N., et al. Pictorial review of the new response evaluation criteria in solid tumors: revised RECIST guideline version 1.1 - What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 2010, 195:281-289.
35. Nishino M., Jackman D.M., Hatabu H., et al. New response evaluation criteria in solid tumors (revised RECIST guideline, version 1.1) in advanced non-small-cell lung cancer: comparison with the original RECIST (version 1.0) and its impact on assessment of tumor response to therapy. AJR Am J Roentgenol 2010, 195:W221-W228.
36. Oxnard G.R., Arcila M.E., Sima C.S., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17:1616-1622.
37. Choi H., Charnsangavej C., Faria S.C., et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with fdG-PET Findings. AJR Am J Roentgenol 2004, 183:1619-1628.
38. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759.
39. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007, 25:1760-1764.
40. Ali K.B., Shah S.N., Wood L.S., et al. Discrepancy between reported progressive disease per radiology report and treating oncologist tumor measurements in patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib. J Clin Oncol 2012, 30:5s. (suppl; abstr 420).
41. Park K., Tsai C.M., Ahn M., et al. ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2012, 30. (suppl; abstr TPS7614).